top of page

Meet Our Dedicated People

They answered our call to action

The power alliance of the Pink Eraser Project includes:

Dedicated Founders

Doctors and Scientists

Visionary Professionals

who each generously contribute to our mission:

Bringing a breast cancer vaccine to market within 5-10 years

The Founders

Michele Young.png

Michele Young

Attorney and Stage 4 breast cancer survivor who organized the effort to pass more comprehensive screening guidelines for early detection

Kristen Dahlgren.png

Kristen Dahlgren

Award winning News Correspondent and medical reporter for NBC, Today Show, and Nightly News for more than 2 decades. Breast Cancer Survivor.

Founders' Story

Kristen and Michele, both breast cancer survivors, met when Kristen interviewed Michele for the NBC Today Show about Michele’s journey to survive stage 4 breast cancer and her quest to save other women from the devastating effects of the disease.

 

Michele had been diagnosed with de novo breast cancer in 2018 and was told to go through her bucket list. In that moment, she decided to save her life and all others.  She researched, traveled to and met with the giants in the field and saw first-hand a revolution taking place that could end breast cancer.

 

Kristen was inspired by Michele, the doctors and the science.  When she decided she was going to leave her career as an award-winning correspondent on NBC, she chose to act on this inspiration and form the Pink Eraser Project with Michele.

Kristen has seen from her career in journalism how even one person can change the world. She, too, realized we are at a unique moment in time when the right collaboration and funding could mean breast cancer vaccines within a decade.  She could not let this opportunity pass without doing everything she could to build a future where no one must go through what she went through.

Together they are leading this historic effort to end breast cancer as we know it.

The Scientists

Nora Disis.png

Dr. Nora Disis

UW/CVI Director

American Cancer Society Clinical Research Professor.

Editor-in-Chief for JAMA Oncology

Pioneering investigator and expert in breast and ovarian cancer immunology.

Dr. Larry Norton

Medical Director, Evelyn H. Lauder Breast Center at Memorial Sloan Kettering

Renowned as a leader in the development of drug treatments for breast cancer.

Founding Scientific Director, BCRF.

Beth Mittendorf.png

Dr. Beth Mittendorf

Brigham and Women's Hospital Vice Chair for Research, Co-Leader, Breast Program, Dana-Farber/Harvard Cancer Center. Director, Breast Immuno-Oncology program. Co-Leader, Parker Institute for Cancer Immunotherapy, Dana-Farber Cancer Institute

Powel Brown.png

Dr. Powel Brown

Molecular biologist and breast medical oncologist, MD Anderson Cancer Center

G. Thomas Budd.png

Dr. G. Thomas Budd

Cleveland Clinic. Recently presented positive data from Phase I Trial of alpha-lactalbumin vaccine in high-risk operable triple negative breast cancer (TNBC) and patients at high genetic risk for TNBC

Shipra Ghandi.png

Dr. Shipra Gandhi

Medical oncologist, breast cancer expert and Assistant Professor of Oncology
Roswell Park Comprehensive Cancer Center (Buffalo, NY)

The Advisors

Sarah Audet.png

Sarah Audett

Principal, Hedgehog & Fox Collaborative

John Cobey.png

John Cobey

Legal Advisor

Libby Coulter.png

Libby Coulton

Marketing & Public Relations

Kiran Dhillon.png

Kiran Dhillon, PhD

Executive Director,
Cancer Vaccine Institute
University of Washington

Judy Lewent.png

Judy Lewent

Former EVP & CFO, Merck & Co.

Andrew W. Lo.png

Andrew W. Lo

Professor of Finance, and the Director of the Laboratory for Financial Engineering at the MIT Sloan School of Management

Jill Morenz.png

Jill Morenz

President & CEO, Aviatra Accelerators

Cheryl Stamm.png

Cheryl Stamm

Nonprofit Mentor. Advisor at Aviatra Accelerators

bottom of page